配体如何揭示G蛋白偶联受体的分子药理学。

How Ligands Illuminate GPCR Molecular Pharmacology.

作者信息

Wacker Daniel, Stevens Raymond C, Roth Bryan L

机构信息

Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27514, USA.

Departments of Biological Sciences and Chemistry, Bridge Institute, University of Southern California, Los Angeles, CA 90089, USA.

出版信息

Cell. 2017 Jul 27;170(3):414-427. doi: 10.1016/j.cell.2017.07.009.

Abstract

G protein-coupled receptors (GPCRs), which are modulated by a variety of endogenous and synthetic ligands, represent the largest family of druggable targets in the human genome. Recent structural and molecular studies have both transformed and expanded classical concepts of receptor pharmacology and have begun to illuminate the distinct mechanisms by which structurally, chemically, and functionally diverse ligands modulate GPCR function. These molecular insights into ligand engagement and action have enabled new computational methods and accelerated the discovery of novel ligands and tool compounds, especially for understudied and orphan GPCRs. These advances promise to streamline the development of GPCR-targeted medications.

摘要

G蛋白偶联受体(GPCRs)可被多种内源性和合成配体调节,是人类基因组中最大的可成药靶点家族。最近的结构和分子研究既改变又扩展了受体药理学的经典概念,并开始阐明结构、化学和功能各异的配体调节GPCR功能的不同机制。这些对配体结合和作用的分子见解催生了新的计算方法,并加速了新型配体和工具化合物的发现,尤其是针对研究不足的孤儿GPCR。这些进展有望简化GPCR靶向药物的开发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索